CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy for bladder cancer. Its lead program is designed to both directly kill cancer cells and stimulate an anti-tumor immune response, with the initial focus on high-risk and intermediate-risk non-muscle invasive bladder cancer (NMIBC). The company is still in development mode and does not yet sell an approved product, so its value proposition is tied primarily to clinical success, regulatory approval, and eventual commercialization. In addition to its core drug program, CG Oncology has built in-house chemistry, manufacturing and controls capabilities and commercial-readiness infrastructure to support a potential launch. The company also has a commercial and development revenue stream through Biovire, a contract manufacturing business focused on fill-and-finish services for novel drugs and medical devices.
−4 686,4 %
−3 985,0 %
+254,7 %
24.63
24.58
| % | |
|---|---|
| Lead oncology drug candidate | 0% Development of cretostimogene grenadenorepvec as a potential therapy for bladder cancer, especially NMIBC. |
| Clinical development services | 0% Preclinical and clinical trial activities supporting the advancement of the lead program. |
| Manufacturing and CMC capabilities | 0% Internal process development, analytical development, and virus-related manufacturing support. |
| License and collaboration revenue | 100% Revenue recognized from licensing and collaboration agreements while the product remains in development. |
| Commercial and development revenue | 0% Biovire fill-and-finish services for novel drugs and medical devices. |
CG Oncology’s primary end customers are patients with high-risk and intermediate-risk NMIBC, but the company’s...
Patients with high-risk or intermediate-risk NMIBC are the intended therapeutic population for cretostimogene because they need effective bladder-sparing treatment options.
Hospitals, clinics, and physicians would administer the therapy and determine adoption based on safety, efficacy, and convenience.
Partners license or collaborate on the platform to gain access to the drug candidate, development know-how, or commercialization rights.
Customers of Biovire buy fill-and-finish services for novel drugs and medical devices, creating non-product revenue.
These stakeholders support enrollment and execution of clinical studies needed to generate regulatory evidence.
CG Oncology is headquartered in the United States and its business is currently centered on U.S...
CG Oncology’s strategy is to advance cretostimogene through late-stage development and position it as a backbone...
The company depends on a single lead asset, so clinical success is the main driver of future value and commercialization potential.
The company has no commercial product history, so building sales, marketing, and market access capabilities is necessary to convert approval into revenue.
Until product sales begin, the company must rely on capital markets and collaboration income to fund operations.
Reliable clinical and future commercial supply is critical for a biologic/oncolytic therapy and can be a differentiator in regulatory review and launch readiness.
CG Oncology is highly exposed to clinical, regulatory, and commercialization risk because it depends entirely on...
The company currently depends entirely on cretostimogene, so any setback in development or approval would materially harm the business.
The company has no approved products, so it cannot generate product revenue unless trials succeed and regulators approve the therapy.
Established and emerging competitors may reach market first or offer better efficacy, safety, or convenience than cretostimogene.
The company expects to need substantial additional funding before product sales are possible, and capital may not be available on favorable terms.
Clinical and future commercial supply depends on complex biologic manufacturing and third-party logistics that can be disrupted.
Operating in a highly regulated industry creates exposure to IP, product liability, privacy, anti-kickback, and other claims.
CBIO · Pharmaceutical Preparations
GNLX · Pharmaceutical Preparations
GENELUX Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing oncolytic vaccinia virus immunotherapies, led by its Olvi-Vec program.
CADL · Biological Products, (No Diagnostic Substances)
ENGN · Biological Products, (No Diagnostic Substances)
CRSP · Biological Products, (No Diagnostic Substances)
CRISPR Therapeutics AG is a gene-editing biopharmaceutical company built around CRISPR/Cas9 technology and the development of gene-based medicines for serious diseases.
GTBP · Pharmaceutical Preparations
: 11/08/2026